7Vote!
The Superficial (Free subscription) | 10 hours ago
Where leathered skin meets hepatitis in a gang-bang of intrigue. MALIBU by Pamela Anderson: Because sometimes giving head on the first date isn't trashy enough. Available at Walmart. Scope Out (20) Pics of Pamela After the Jump Photos: WENN... ...read full story
7Vote!
Detroit Free Press (Free subscription) | yesterday
TODAY'S SUBJECT: Debbie and Ted Green, founders of the Greenview Foundation's Hepatitis C Research Fund
3Vote!
CBC.ca (Free subscription) | 11/06/2009
Canadian taxpayers could be on the hook for millions of dollars in health care costs unless something is done to stop the spread of hepatitis C among injection drug users in federal prisons, a House of Commons committee heard.
5Vote!
Kukla's Korner (Free subscription) | 11/06/2009
from Mark Everson of the NY Post, When Elias returned from Hepatitis A, which he contracted during the lockout, on Jan. 3, 2006, the Devils were a game under .500 and in serious danger of missing the playoffs. They went 30-9-4 after his return and he had 45 points in his 38 games. “That was ridiculous,” Elias said. “Don’t expect that from me, even though I’d like to play...
3Vote!
An English Physician (Free subscription) | 11/06/2009
This happened in Muscat, in 'Oman. He was a student in the university. He had just returned from his native village to the campus after a vacation. He was referred urgently because he had developed jaundice. He told me he had felt hot and unwell for maybe 10 days. He had diarrhoea, not severe. He had rather vague abdominal discomfort. He had noticed his eyes were yellow the previous evening; today...
3Vote!
Denver Christian Docs (Free subscription) | 11/05/2009
Just came across my Email that there is a new strain of Hepatitis C among gay men in New York City. As a pathologist I really dislike Hep C. It gets lab people all the time with needle sticks, etc. I'm a lot more afraid of Hep C than of HIV. And a new strain, efficiently sexually transmitted, with rapid liver damage?
5Vote!
SeekingAlpha.com (Free subscription) | 11/05/2009
Zacks.com submits: Human Genome Sciences, Inc. ( HGSI ) reported third quarter net loss of $49 million or 32 cents per share, in-line with the Zacks Consensus Estimate. The company reported a net loss of $74.2 million or 50 cents in the year ago quarter. The lower net loss for the quarter was primarily attributable to increased revenues from manufacturing and development services and lower operating...
4Vote!
Business Wire (Free subscription) | 11/05/2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today reported financial results for the third quarter and nine months ended September 30, 2009. “We have continued development of our pipeline of drug candidates targeted to Toll-like receptors for potential applications in chronic hepatitis C virus infection and autoimmune diseases, and to support our partnered programs...
3Vote!
Medical News Today (Free subscription) | 11/04/2009
Tibotec announced results of a new study (VX950-C208), which showed that sustained virologic response (SVR) was achieved in more than 80 percent of treatment-naïve patients with chronic genotype 1 hepatitis C virus (HCV) who took telaprevir, administered either every 8 hours or every 12 hours, in combination with standard of care.
3Vote!
Medindia Health News (Free subscription) | 11/04/2009
US lawmakers led by Asian Americans on Monday pushed to ramp up spending to fight hepatitis B and C, warning that the di
3Vote!
Medical News Today (Free subscription) | 11/04/2009
The nucleoside analogue entecavir (Baraclude, Bristol-Myers Squibb) achieves a high response rate and progressive decline in liver stiffness in patients with chronic hepatitis B, according to results from the first study in 'real-life' clinical practice reported at the Annual Meeting of the American Association for the Study of Liver Diseases (31 October - 3 November, 2009).
4Vote!
Business Wire (Free subscription) | 11/04/2009
STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Data were presented from the phase IIa trial (OPERA-1) for TMC435 at the ongoing 60th annual meeting of the American Association for the Study of Liver Diseases in Boston, USA. TMC435 is an investigational protease inhibitor, being developed by Tibotec in collaboration with Medivir, for the treatment of hepatitis C virus (HCV). Data for TMC435 in...
3Vote!
Xconomy (Free subscription) | 11/04/2009
A number of New England’s life sciences companies had good news to report this week. —Cambridge, MA-based Vertex Pharmaceuticals (NASDAQ: VRTX) reported results from clinical trials that indicate its experimental hepatitis C drug, telaprevir, could work well for patients who haven’t responded fully to standard treatments, and could be as effective taken twice a day as [...]
5Vote!
SeekingAlpha.com (Free subscription) | 11/04/2009
ChinaBio Today submits: Sinovac Biotech Ltd. ( SVA ) will move the home for its stock listing from the NYSE Amex to the NASDAQ Global Market. The reason given for the change was “greater liquidity.” Target day for the transfer is November 16. Although most NASDAQ companies use a four-letter symbol, Sinovac will be allowed to keep its current three-letter identifier, SVA, so the new listing...
3Vote!
Medical News Today (Free subscription) | 11/04/2009
Enzo Biochem Inc. (NYSE:ENZ) announced today that favorable results of the Company's clinical trial for treatment of non-alcoholic steatohepatitis (NASH) were presented at the annual meeting of the American Association for the Study of Liver Diseases.
4Vote!
saxondc3jj | 10/31/2009
Buy Rebetol without prescription - Click Here! >>> Rebetol is used for treatment of hepatitis C infection in certain patients when used in combination with interferon. Order Rebetol at one of the trusted online pharmacies and save your money. Check Prices and Buy Rebetol Important! Free Pills with EVERY order! No prescription is needed! Safe and Secured 100% Best Customer service Click Here to Order...
3Vote!
aarkstore | 10/29/2009
Hepatitis C Therapy Area Pipeline Report contains detailed information on the hepatitis c drug pipeline. This report provides insight into the pipeline status of hepatitis c drugs by company and by stage as well as a summary of the latest news and developments in this area. Scope of the report: Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage,...
3Vote!
aarkstore | 10/29/2009
Hepatitis B Therapy Area Pipeline Report contains detailed information on the hepatitis b drug pipeline. This report provides insight into the pipeline status of hepatitis b drugs by company and by stage as well as a summary of the latest news and developments in this area. Scope of the report: Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage,...